IMRX Company Profile and Key Details
Immuneering Corporation
IMRX Stock Price Chart
Stock Price Today
Immuneering Corporation (IMRX) stock declined over -0.47%, trading at $2.11 on NASDAQ, down from the previous close of $2.12. The stock opened at $2.10, fluctuating between $2.05 and $2.14 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
Company Information
| Employees | 66 |
| Beta | -0.4 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | -1% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Immuneering Corporation (NASDAQ: IMRX) stock price is $2.11 in the last trading session. During the trading session, IMRX stock reached the peak price of $2.14 while $2.05 was the lowest point it dropped to. The percentage change in IMRX stock occurred in the recent session was -0.47% while the dollar amount for the price change in IMRX stock was -$0.01.
The NASDAQ listed IMRX is part of Biotechnology industry that operates in the broader Healthcare sector. Immuneering Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Brett M. Hall Ph.D.
Chief Scientific Officer
Mr. Michael D. Bookman J.D.
Chief Legal Officer & Sec.
Ms. Paula George C.P.A.
Director of Accounting & Operations and Assistant Corporation Controller
Mr. Steve Bressler
Vice President & Head of Information Technology
Mr. Harold E. Brakewood
Chief Bus. Officer
Ms. Paula George CPA
Director of Accounting & Operations and Assistant Corporation Controller
Ms. Mallory Morales CPA
Vice President of Fin., Principal Financial & Accounting Officer and Treasurer
Ms. Leah R. Neufeld
Chief People Officer
Ms. Mallory Morales C.P.A.
Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer
Dr. Mohamedi Kagalwala M.B.A., Ph.D.
Head of Neuroscience Devel.
Dr. Scott Barrett M.D.
Chief Medical Officer
Dr. Peter King Ph.D.
Head of Discovery & Vice President
Dr. Rajaraman Krishnan Ph.D.
Head of Neuroscience Discovery
Dr. Andrew Lysaght Ph.D.
Vice President & Head of Bioinformatics
Dr. J.L. Ross Ph.D.
Vice President & Head of Neuroscience
Dr. Benjamin J. Zeskind M.B.A., MBA, Ph.D.
Co-Founder, Pres, Chief Executive Officer & Director
Dr. Praveen Nair Ph.D.
Head of Translational Pharmacology & Vice President
IMRX's closing price is 111% higher than its 52-week low of $1.00 where as its distance from 52-week high of $7.68 is -72.53%.
Number of IMRX employees currently stands at 66.
Official Website of IMRX is: https://immuneering.com
IMRX could be contacted at phone 617 500 8080 and can also be accessed through its website. IMRX operates from 245 Main Street, Cambridge, MA 02142, United States.
IMRX stock volume for the day was 486.82K shares. The average number of IMRX shares traded daily for last 3 months was 2.02M.
The market value of IMRX currently stands at $65.52M with its latest stock price at $2.11 and 31.05M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com